
  
    
      
        
        The_DT Antihypertensive_NNP and_CC Lipid_NNP Lowering_NNP Treatment_NNP to_TO
        Prevent_VB Heart_NNP Attack_NNP Trial_NNP (_( ALLHAT_NNP )_) is_VBZ a_DT randomized_JJ ,_,
        two-component_JJ clinical_JJ trial_NN sponsored_VBN by_IN the_DT National_NNP
        Heart_NNP ,_, Lung_NNP ,_, and_CC Blood_NNP Institute_NNP (_( NHLBI_NNP )_) ._. A_DT double-blind_JJ ,_,
        active-controlled_JJ hypertension_NN component_NN is_VBZ designed_VBN to_TO
        compare_VB the_DT rate_NN of_IN fatal_JJ coronary_JJ heart_NN disease_NN (_( CHD_NNP )_) or_CC
        nonfatal_NN myocardial_NN infarction_NN (_( MI_NNP )_) (_( the_DT primary_NN endpoint_NN )_)
        in_IN high-risk_JJ hypertensive_JJ participants_NNS ,_, aged_VBN 55_CD years_NNS or_CC
        older_JJR ,_, between_IN those_DT randomized_JJ to_TO treatment_NN initiated_VBN with_IN
        a_DT diuretic_JJ (_( chlorthalidone_NN )_) and_CC treatment_NN initiated_VBN with_IN
        each_DT of_IN three_CD alternative_NN antihypertensive_JJ drugs_NNS :_: a_DT
        calcium-channel_JJ blocker_NN (_( amlodipine_NN )_) ,_, an_DT
        angiotensin-converting_JJ enzyme_NN (_( ACE_NNP )_) -_: inhibitor_NN (_( lisinopril_NN )_) ,_,
        or_CC an_DT alpha-adrenergic_JJ blocker_NN (_( doxazosin_NN )_) ._. An_DT open-label_JJ
        lipid-lowering_JJ component_NN is_VBZ designed_VBN to_TO determine_VB if_IN
        lowering_VBG LDL_NNP cholesterol_NN with_IN pravastatin_NN compared_VBN to_TO
        "_'' usual_JJ care_NN "_'' reduces_VBZ all-cause_JJ mortality_NN in_IN a_DT subset_NN of_IN
        moderately_RB hypercholesterolemic_JJ patients_NNS ._. Randomization_NNP to_TO
        the_DT hypertension_NN component_NN began_VBD in_IN February_NNP ,_, 1994_CD ,_, and_CC
        continued_VBD through_IN January_NNP ,_, 1998_CD ,_, with_IN 42_CD ,_, 418_CD participants_NNS
        recruited_VBN at_IN 623_CD clinical_JJ centers_NNS in_IN the_DT United_NNP States_NNPS ,_,
        Canada_NNP ,_, Puerto_NNP Rico_NNP and_CC the_DT US_NNP Virgin_NNP Islands_NNP ._.
        Randomization_NNP of_IN 10_CD ,_, 355_CD participants_NNS into_IN the_DT lipid_NN trial_NN
        ended_VBN May_NNP 31_CD ,_, 1998_CD ._. Follow-up_JJ on_IN all_DT participants_NNS continued_VBD
        through_IN March_NNP ,_, 2002_CD [_NN 1_CD ]_NN ._.
        Following_VBG independent_JJ reviews_NNS by_IN the_DT Data_NNP and_CC Safety_NNP
        Monitoring_NN Board_NNP (_( DSMB_NNP )_) on_IN January_NNP 6_CD ,_, 2000_CD ,_, and_CC by_IN an_DT Ad_NNP
        Hoc_NNP Committee_NNP on_IN January_NNP 21_CD ,_, 2000_CD ,_, the_DT Director_NNP of_IN the_DT
        National_NNP Heart_NNP ,_, Lung_NNP ,_, and_CC Blood_NNP Institute_NNP accepted_VBD a_DT
        recommendation_NN to_TO discontinue_VB the_DT doxazosin_NN treatment_NN arm_NN
        of_IN the_DT antihypertensive_JJ trial_NN ._. This_DT recommendation_NN was_VBD
        based_VBN on_IN the_DT low_JJ probability_NN of_IN doxazosin_NN showing_VBG benefit_NN
        over_IN chlorthalidone_NN for_IN the_DT primary_JJ endpoint_NN ,_, as_RB well_RB as_IN
        the_DT significantly_RB increased_VBN occurrence_NN of_IN the_DT secondary_JJ
        endpoint_NN ,_, combined_VBD cardiovascular_JJ disease_NN (_( CVD_NNP )_)
        (_( encompassing_VBG CHD_NNP deaths_NNS ,_, nonfatal_NN MI_NNP ,_, stroke_NN ,_, coronary_JJ
        revascularization_NN procedures_NNS [_NN coronary_JJ artery_NN bypass_NN graft_NN
        or_CC CABG_NNP ,_, percutaneous_JJ transluminal_NN coronary_JJ angioplasty_NN or_CC
        PTCA_NNP /_NN stent_NN ]_NN ,_, angina_NN [_NN hospitalized_VBN or_CC treated_VBN as_IN an_DT
        outpatient_NN ]_NN ,_, heart_NN failure_NN [_NN HF_NNP /_NN treated_VBN in_IN the_DT hospital_NN or_CC
        as_IN an_DT outpatient_NN ]_NN ,_, and_CC peripheral_JJ arterial_NN disease_NN
        [_NN in-hospital_JJ or_CC outpatient_NN revascularization_NN ]_NN )_) in_IN the_DT
        doxazosin_NN arm_NN (_( RR_NNP 1_CD ._. 25_CD ;_: 95_CD %_NN CI_NNP ,_, 1_CD ._. 17_CD -_: 1_CD ._. 33_CD ;_: 
        P_NN <_NN ._. 001_CD )_) ,_, with_IN a_DT doubling_NN of_IN risk_NN
        of_IN HF_NNP (_( fatal_JJ ,_, hospitalized_VBN and_CC treated_VBN but_CC nonhospitalized_JJ )_)
        (_( RR_NNP 2_CD ._. 04_CD ;_: 95_CD %_NN CI_NNP ,_, 1_CD ._. 79_CD -_: 2_CD ._. 32_CD ;_: 
        P_NN <_NN ._. 001_CD )_) ._. When_WRB only_RB fatal_JJ and_CC
        hospitalized_VBN HF_NNP were_VBD analyzed_VBN ,_, the_DT large_JJ difference_NN
        remained_VBD (_( RR_NNP 1_CD ._. 83_CD ;_: 95_CD %_NN CI_NNP ,_, 1_CD ._. 58_CD -_: 2_CD ._. 13_CD ;_: 
        P_NN <_NN ._. 001_CD )_) ._. The_DT findings_NNS and_CC
        operational_JJ aspects_NNS of_IN stopping_VBG the_DT doxazosin_NN arm_NN of_IN the_DT
        study_NN have_VBP been_VBN previously_RB described_VBN [_NN 2_CD 3_CD 4_CD ]_NN ._.
        The_DT observed_VBN increase_NN in_IN HF_NNP in_IN the_DT doxazosin_NN group_NN as_IN
        compared_VBN to_TO the_DT chlorthalidone_NN group_NN led_VBN to_TO several_JJ
        additional_JJ analyses_NNS aimed_VBN toward_IN validation_NN of_IN the_DT
        diagnoses_NNS ,_, with_IN a_DT focus_NN on_IN hospitalized_VBN and_CC fatal_JJ HF_NNP ._. The_DT
        purposes_NNS of_IN these_DT analyses_NNS were_VBD :_: 1_LS )_) to_TO evaluate_VB the_DT reality_NN
        of_IN HF_NNP cases_NNS ,_, i_NNP ._. e_SYM ._. whether_IN diagnosis_NN ,_, management_NN ,_, and_CC
        clinical_JJ course_NN were_VBD what_WP might_MD be_VB expected_VBN ,_, and_CC 2_LS )_) to_TO
        compare_VB these_DT features_NNS between_IN the_DT two_CD treatment_NN
        groups_NNS ._.
      
      
        Methods_NNP
        
          Study_NNP Design_NNP
          The_DT rationale_NN and_CC design_NN of_IN ALLHAT_NNP are_VBP described_VBN in_IN
          detail_NN elsewhere_RB [_NN 1_CD ]_NN ._. Briefly_NNP ,_, those_DT eligible_NN for_IN
          randomization_NN had_VBD systolic_JJ blood_NN pressure_NN (_( SBP_NNP )_) of_IN at_IN
          least_JJS 140_CD mm_NN Hg_NNP and_CC /_NN or_CC diastolic_JJ blood_NN pressure_NN of_IN at_IN
          least_JJS 90_CD mm_NN Hg_NNP ,_, or_CC took_VBD medication_NN for_IN hypertension_NN ,_, and_CC
          had_VBD at_IN least_JJS one_CD other_JJ risk_NN factor_NN for_IN CHD_NNP events_NNS ._. Risk_NN
          factors_NNS included_VBD previous_JJ MI_NNP or_CC stroke_NN ,_, left_VBD ventricular_NN
          hypertrophy_NN by_IN electrocardiogram_NN or_CC echocardiogram_NN ,_,
          history_NN of_IN type_NN 2_CD diabetes_NN ,_, current_JJ cigarette_NN smoking_NN ,_,
          and_CC low_JJ high-density_JJ lipoprotein_NN (_( HDL_NNP )_) level_NN ._.
          The_DT primary_JJ endpoint_NN of_IN the_DT blood_NN pressure_NN (_( BP_NNP )_) trial_NN
          is_VBZ the_DT composite_NN of_IN nonfatal_NN MI_NNP and_CC fatal_JJ CHD_NNP ._. The_DT four_CD
          protocol-defined_JJ secondary_JJ clinical_JJ outcomes_NNS are_VBP
          all-cause_JJ mortality_NN ,_, combined_VBD CHD_NNP (_( including_VBG CHD_NNP death_NN ,_,
          nonfatal_NN MI_NNP ,_, coronary_JJ revascularization_NN procedures_NNS and_CC
          hospitalized_VBN angina_NN )_) ,_, stroke_NN ,_, and_CC combined_VBD CVD_NNP (_( including_VBG
          CHD_NNP death_NN ,_, nonfatal_NN MI_NNP ,_, stroke_NN ,_, coronary_JJ
          revascularization_NN procedures_NNS ,_, angina_NN treated_VBN in_IN the_DT
          hospital_NN or_CC as_IN an_DT outpatient_NN ,_, lower_JJR extremity_NN peripheral_JJ
          arterial_NN disease_NN treated_VBN in_IN the_DT hospital_NN or_CC with_IN
          outpatient_NN revascularization_NN ,_, and_CC HF_NNP ,_, fatal_JJ or_CC treated_VBN in_IN
          the_DT hospital_NN or_CC as_IN an_DT outpatient_NN )_) ._.
          The_DT validation_NN of_IN HF_NNP diagnosis_NN entailed_VBN answering_VBG
          several_JJ questions_NNS :_:
          1_LS ._. Did_VBD HF_NNP cases_NNS meet_VBP ALLHAT_NNP diagnostic_JJ criteria_NNS ?_.
          2_LS ._. Were_VBD baseline_NN characteristics_NNS and_CC medical_JJ
          management_NN for_IN HF_NNP cases_NNS as_IN expected_VBN and_CC similar_JJ across_IN
          the_DT drug_NN groups_NNS ?_.
          3_LS ._. Were_VBD prevalence_NN and_CC severity_NN of_IN systolic_JJ
          dysfunction_NN as_IN expected_VBN and_CC similar_JJ across_IN drug_NN
          groups_NNS ?_.
          4_LS ._. Were_VBD case-fatality_JJ rates_NNS as_IN expected_VBN and_CC similar_JJ
          across_IN drug_NN groups_NNS ?_.
          Unless_IN otherwise_RB specified_VBN ,_, all_DT data_NNS for_IN these_DT
          analyses_NNS were_VBD collected_VBN as_IN of_IN December_NNP ,_, 1999_CD ._.
        
        
          Heart_NNP Failure_NN Diagnosis_NNP
          At_IN each_DT follow-up_JJ clinic_NN visit_NN the_DT occurrence_NN of_IN study_NN
          clinical_JJ events_NNS was_VBD assessed_VBN ,_, and_CC ,_, if_IN identified_VBN by_IN the_DT
          clinical_JJ investigator_NN ,_, reported_VBD on_IN an_DT endpoint_NN form_NN ._. For_IN
          each_DT event_NN involving_VBG hospitalization_NN ,_, a_DT hospital_NN
          discharge_NN summary_NN or_CC expiration_NN summary_NN was_VBD to_TO be_VB
          submitted_VBN ,_, and_CC for_IN each_DT death_NN a_DT death_NN certificate_NN was_VBD
          required_VBN ._. Endpoint_NNP forms_NNS and_CC supporting_VBG documentation_NN
          were_VBD reviewed_VBN at_IN the_DT ALLHAT_NNP Clinical_NNP Trials_NNP Center_NNP (_( CTC_NNP )_)
          for_IN accuracy_NN and_CC appropriateness_NN ._. When_WRB a_DT discrepancy_NN or_CC
          ambiguity_NN was_VBD found_VBN ,_, the_DT CTC_NNP sent_VBD a_DT written_VBN query_NN to_TO the_DT
          Principal_NN Investigator_NNP ,_, who_WP retained_VBD the_DT final_JJ word_NN
          concerning_VBG the_DT diagnosis_NN or_CC cause_NN of_IN death_NN ._. A_DT random_JJ 10_CD %_NN
          sample_NN of_IN strokes_NNS ,_, nonfatal_NN MIs_NNP and_CC CHD_NNP deaths_NNS was_VBD
          selected_VBN for_IN blinded_JJ quality_NN control_NN evaluation_NN by_IN the_DT
          ALLHAT_NNP Endpoints_NNP Subcommittee_NNP ;_: for_IN these_DT cases_NNS additional_JJ
          documentation_NN was_VBD requested_VBN ._.
          No_DT such_JJ routine_JJ Endpoints_NNP Subcommittee_NNP quality_NN control_NN
          was_VBD initially_RB planned_VBN for_IN reported_VBD HF_NNP ._. However_RB ,_, the_DT
          Subcommittee_NNP was_VBD subsequently_RB called_VBN upon_IN to_TO evaluate_VB a_DT
          random_JJ sample_NN of_IN reported_VBD fatal_JJ and_CC hospitalized_VBN nonfatal_NN
          HF_NNP events_NNS ._. As_IN this_DT occurred_VBN prior_RB to_TO the_DT termination_NN of_IN
          the_DT doxazosin_NN arm_NN ,_, neither_DT the_DT chair_NN nor_CC the_DT members_NNS of_IN
          the_DT Subcommittee_NNP was_VBD informed_VBN of_IN the_DT major_JJ reason_NN for_IN
          this_DT review_NN ,_, namely_RB ,_, the_DT trend_NN toward_IN a_DT higher_JJR HF_NNP event_NN
          rate_NN in_IN the_DT doxazosin_NN group_NN compared_VBN to_TO the_DT
          chlorthalidone_NN group_NN ._. The_DT Subcommittee_NNP was_VBD told_VBN that_IN the_DT
          review_NN was_VBD undertaken_VBN at_IN the_DT request_NN of_IN the_DT DSMB_NNP to_TO
          address_VB the_DT reliability_NN and_CC validity_NN of_IN reported_VBD HF_NNP
          events_NNS ._. This_DT evaluation_NN consisted_VBD of_IN fifty_NN events_NNS ,_, evenly_RB
          distributed_VBN across_IN the_DT four_CD treatment_NN groups_NNS ,_, reported_VBD as_IN
          fatal_JJ or_CC hospitalized_VBN nonfatal_NN HF_NNP and_CC with_IN
          protocol-required_JJ documentation_NN (_( discharge_NN summary_NN for_IN
          hospitalized_VBN events_NNS ,_, death_NN certificates_NNS for_IN deaths_NNS )_) ._.
          Additional_JJ material_NN was_VBD not_RB requested_VBN ,_, since_IN this_DT would_MD
          have_VB posed_VBN an_DT undue_JJ burden_NN on_IN the_DT clinical_JJ site_NN staff_NN and_CC
          would_MD have_VB risked_VBD raising_VBG questions_NNS about_IN emerging_VBG
          differences_NNS among_IN treatment_NN groups_NNS ._.
          The_DT ALLHAT_NNP definition_NN of_IN HF_NNP ,_, used_VBD previously_RB in_IN the_DT
          Systolic_NNP Hypertension_NNP in_IN the_DT Elderly_JJ Program_NN (_( SHEP_NNP )_) [_NN 5_CD ]_NN
          ,_, includes_VBZ "_'' patients_NNS with_IN clear-cut_JJ signs_NNS or_CC symptoms_NNS of_IN
          left_VBD or_CC right_JJ ventricular_NN dysfunction_NN that_DT cannot_NN be_VB
          attributed_VBN to_TO other_JJ causes_NNS ._. ._. ._. "_'' The_DT diagnosis_NN of_IN HF_NNP must_MD
          include_VB at_IN least_JJS one_CD of_IN four_CD stated_VBN symptoms_NNS [_NN paroxysmal_JJ
          nocturnal_NN dyspnea_NN ,_, dyspnea_NN at_IN rest_NN ,_, New_NNP York_NNP Heart_NNP
          Classification_NNP functional_JJ class_NN III_NNP (_( for_IN definition_NN see_VB
          Additional_JJ Information_NNP ,_, Item_NNP 1_LS )_) ,_, or_CC orthopnea_NN ]_NN ,_, and_CC one_CD
          of_IN seven_CD stated_VBN signs_NNS (_( rales_NNS ,_, 2_CD +_NN or_CC greater_JJR ankle_NN edema_NN ,_,
          tachycardia_NN of_IN 120_CD beats_VBZ /_NN minute_NN or_CC more_JJR after_IN five_CD
          minutes_NNS at_IN rest_NN ,_, cardiomegaly_RB by_IN chest_NN x-ray_JJ ,_, chest_NN x-ray_JJ
          characteristic_NN of_IN HF_NNP ,_, S_NNP 
          3_CD gallop_NN ,_, or_CC jugular_NN venous_JJ
          distention_NN )_) ._. Since_IN lower_JJR extremity_NN edema_NN or_CC exertional_NN
          dyspnea_NN may_MD be_VB due_JJ to_TO non-cardiac_JJ causes_NNS ,_, the_DT presence_NN of_IN
          either_DT of_IN these_DT alone_RB ,_, without_IN other_JJ indications_NNS of_IN heart_NN
          failure_NN ,_, is_VBZ not_RB sufficient_JJ for_IN a_DT diagnosis_NN of_IN HF_NNP ._. Study_NN
          guidelines_NNS caution_VBP against_IN a_DT hasty_JJ HF_NNP diagnosis_NN in_IN
          patients_NNS with_IN severe_JJ pulmonary_JJ disease_NN ,_, including_VBG chronic_JJ
          obstructive_JJ pulmonary_JJ disease_NN (_( COPD_NNP )_) ,_, pneumonia_NN ,_, or_CC other_JJ
          severe_JJ ,_, documented_VBN lung_NN disease_NN ._.
        
        
          Baseline_NNP Characteristics_NNP and_CC Medical_NNP
          Management_NNP
          Baseline_NNP characteristics_NNS of_IN chlorthalidone_NN and_CC
          doxazosin_NN participants_NNS were_VBD compared_VBN ._. These_DT analyses_NNS were_VBD
          stratified_JJ by_IN HF_NNP outcome_NN :_: 1_LS )_) fatal_JJ and_CC hospitalized_VBN HF_NNP ;_:
          2_LS )_) treated_VBN ,_, non-hospitalized_JJ HF_NNP ;_: and_CC ,_, 3_LS )_) no_DT HF_NNP ._.
          Post-_NNP HF_NNP event_NN medical_JJ management_NN may_MD provide_VB
          additional_JJ evidence_NN of_IN the_DT physicians_NNS '_POS confidence_NN in_IN the_DT
          HF_NNP diagnosis_NN ._. The_DT post-event_JJ use_NN of_IN open-label_JJ diuretics_NNS ,_,
          ACE-inhibitors_NNP ,_, and_CC beta-blockers_JJ ,_, i_NNP ._. e_SYM ._. ,_, accepted_VBD
          treatments_NNS for_IN HF_NNP [_NN 6_CD 7_CD 8_CD 9_CD ]_NN ,_, was_VBD compared_VBN between_IN
          doxazosin_NN and_CC chlorthalidone_NN groups_NNS ,_, as_IN was_VBD the_DT
          proportion_NN in_IN each_DT group_NN of_IN those_DT who_WP remained_VBD on_IN
          assigned_VBN blinded_JJ medication_NN after_IN the_DT event_NN ._. (_( For_IN study_NN
          guidelines_NNS regarding_VBG the_DT use_NN and_CC reporting_NN of_IN open-label_JJ
          medicines_NNS of_IN the_DT same_JJ class_NN as_IN the_DT blinded_JJ drugs_NNS ,_, see_VB
          Additional_JJ Information_NNP ,_, Items_NNS 2_CD and_CC 3_CD ._. )_)
        
        
          Ejection_NNP Fraction_NNP Review_NNP
          A_DT CTC_NNP physician_NN plus_CC non-medical_JJ staff_NN reviewed_VBN in_IN a_DT
          blinded_JJ fashion_NN 361_CD hospitalized_VBN HF_NNP events_NNS (_( representing_VBG
          278_CD participants_NNS )_) for_IN ejection_NN fraction_NN data_NNS :_: looking_VBG for_IN
          whether_IN an_DT ejection_NN fraction_NN was_VBD measured_VBN ,_, the_DT method_NN
          utilized_JJ ,_, and_CC the_DT measurement_NN ._. Results_NNS ,_, tabulated_JJ by_IN
          randomization_NN groups_NNS ,_, reflected_VBD data_NNS that_WDT had_VBD been_VBN
          collected_VBN up_RP to_TO July_NNP ,_, 1999_CD ,_, the_DT time_NN of_IN the_DT review_NN ._.
        
        
          Case-_NNP Fatality_NNP Rates_NNS and_CC Causes_NNP of_IN Death_NN
          As_IN a_DT measure_NN of_IN the_DT diagnostic_JJ validity_NN and_CC severity_NN
          of_IN HF_NNP and_CC comparability_NN between_IN drug_NN groups_NNS ,_,
          time-from-event-to-death_JJ analyses_NNS of_IN participants_NNS with_IN
          hospitalized_VBN or_CC treated_VBN HF_NNP were_VBD compared_VBN between_IN the_DT two_CD
          groups_NNS ._. Causes_NNP of_IN death_NN of_IN such_JJ participants_NNS were_VBD also_RB
          compared_VBN in_IN the_DT doxazosin_NN and_CC chlorthalidone_NN groups_NNS ._.
        
        
          Statistical_NNP Analyses_NNS
          Data_NNP were_VBD analyzed_VBN according_VBG to_TO participants_NNS '_POS
          randomization_NN assignments_NNS and_CC HF_NNP outcome_NN status_NN ,_,
          regardless_RB of_IN subsequent_JJ medication_NN adherence_NN ._. The_DT
          Kaplan-_NNP Meier_NNP method_NN was_VBD utilized_JJ in_IN calculating_VBG
          cumulative_JJ event_NN rates_NNS ._. Descriptive_NNP statistics_NNS by_IN
          treatment_NN groups_NNS were_VBD presented_VBN for_IN baseline_NN
          characteristics_NNS ,_, HF_NNP ascertainment_NN ,_, ejection_NN fractions_NNS and_CC
          use_NN of_IN HF_NNP medications_NNS ._. Comparability_NNP of_IN baseline_NN
          characteristics_NNS of_IN the_DT treatment_NN and_CC HF_NNP outcome_NN groups_NNS
          was_VBD ascertained_JJ by_IN the_DT Ï‡_NN 2_CD test_NN for_IN categorical_JJ variables_NNS
          and_CC standard_JJ normal_JJ (_( z_SYM )_) test_NN for_IN continuous_JJ
          variables_NNS ._.
        
      
      
        Results_NNS
        
          Heart_NNP Failure_NN Diagnostic_NNP Criteria_NNP
          The_DT blinded_JJ review_NN by_IN the_DT Endpoints_NNP Subcommittee_NNP of_IN 50_CD
          fatal_JJ or_CC hospitalized_VBN HF_NNP events_NNS from_IN the_DT 4_CD drug_NN groups_NNS
          determined_VBD 11_CD (_( 22_CD %_NN )_) to_TO have_VB incomplete_JJ data_NNS for_IN a_DT
          definitive_JJ review_NN ._. Of_IN the_DT remaining_VBG 39_CD ,_, 33_CD (_( 85_CD %_NN )_) were_VBD
          confirmed_VBN to_TO have_VB HF_NNP by_IN one_CD or_CC both_DT reviewers_NNS ._. For_IN both_DT
          the_DT chlorthalidone_NN and_CC doxazosin_NN groups_NNS ,_, the_DT diagnosis_NN of_IN
          HF_NNP was_VBD confirmed_VBN in_IN 90_CD %_NN (_( 18_CD /_NN 20_CD )_) ._.
        
        
          Baseline_NNP Characteristics_NNP
          Baseline_NNP characteristics_NNS for_IN the_DT doxazosin_NN and_CC
          chlorthalidone_NN treatment_NN groups_NNS ,_, stratified_JJ for_IN HF_NNP
          status_NN ,_, are_VBP described_VBN in_IN Table_NNP 1_CD ._.
          Baseline_NNP characteristics_NNS of_IN doxazosin_NN and_CC
          chlorthalidone_NN participants_NNS with_IN subsequent_JJ hospitalized_VBN
          or_CC fatal_JJ HF_NNP were_VBD compared_VBN ._. Doxazosin_NNP participants_NNS with_IN
          hospitalized_VBN or_CC fatal_JJ HF_NNP had_VBD a_DT higher_JJR baseline_NN SBP_NNP than_IN
          the_DT chlorthalidone_NN participants_NNS (_( 150_CD ._. 1_LS vs_NNS ._. 147_CD ._. 8_CD mm_NN Hg_NNP at_IN
          the_DT randomization_NN visit_NN )_) ._. More_JJR doxazosin_NN participants_NNS had_VBD
          LVH_NNP by_IN ECG_NNP (_( 22_CD ._. 3_LS %_NN vs_NNS ._. 20_CD ._. 5_LS %_NN of_IN chlorthalidone_NN
          participants_NNS )_) ;_: slightly_RB more_JJR chlorthalidone_NN than_IN
          doxazosin_NN participants_NNS had_VBD LVH_NNP by_IN echocardiogram_NN ._. Several_JJ
          eligibility_NN risk_NN factors_NNS ,_, including_VBG previous_JJ MIs_NNP or_CC
          strokes_NNS ,_, coronary_JJ revascularization_NN procedures_NNS ,_, other_JJ
          atherosclerotic_JJ cardiovascular_JJ disease_NN (_( ASCVD_NNP )_) ,_, and_CC ST-T_NNP
          wave_NN changes_NNS ,_, were_VBD reported_VBN more_RBR often_RB in_IN chlorthalidone_NN
          than_IN in_IN doxazosin_NN participants_NNS ,_, though_IN the_DT differences_NNS
          were_VBD not_RB significant_JJ ._. Chlorthalidone_NNP and_CC doxazosin_NN
          participants_NNS with_IN hospitalized_VBN or_CC fatal_JJ HF_NNP had_VBD similar_JJ
          pre-trial_JJ antihypertensive_JJ treatment_NN durations_NNS ._. None_NN of_IN
          these_DT differences_NNS was_VBD significant_JJ at_IN 
          P_NN <_NN ._. 05_CD ._.
          Participants_NNS with_IN HF_NNP events_NNS displayed_VBD higher_JJR rates_NNS of_IN
          most_JJS cardiovascular_JJ risk_NN factors_NNS compared_VBN to_TO those_DT
          without_IN HF_NNP events_NNS ._. Approximately_RB 35_CD -_: 36_CD %_NN of_IN chlorthalidone_NN
          and_CC doxazosin_NN participants_NNS with_IN fatal_JJ or_CC hospitalized_VBN HF_NNP
          had_VBD reported_VBN prior_RB MI_NNP or_CC stroke_NN as_IN baseline_NN eligibility_NN
          risk_NN factors_NNS ,_, compared_VBN to_TO 22_CD -_: 23_CD %_NN of_IN those_DT without_IN HF_NNP (_( 
          P_NN <_NN ._. 001_CD )_) ._. Participants_NNS with_IN
          hospitalized_VBN /_NN fatal_JJ HF_NNP had_VBD significantly_RB higher_JJR rates_NNS of_IN
          pre-randomization_JJ coronary_JJ artery_NN bypass_NN grafts_NNS (_( CABGs_NNP )_)
          and_CC coronary_JJ angioplasties_NNS (_( 19_CD -_: 23_CD %_NN of_IN those_DT with_IN HF_NNP vs_NNS ._.
          13_CD %_NN of_IN those_DT without_IN ;_: 
          P_NN <_NN ._. 001_CD )_) and_CC other_JJ
          atherosclerotic_JJ cardiovascular_JJ disease_NN (_( ASCVD_NNP )_) (_( 29_CD -_: 33_CD %_NN of_IN
          those_DT with_IN HF_NNP vs_NNS ._. 23_CD -_: 25_CD %_NN of_IN those_DT without_IN ;_: 
          P_NN <_NN ._. 001_CD )_) ._. Diabetes_NNP as_IN a_DT
          baseline_NN risk_NN factor_NN occurred_VBD more_RBR frequently_RB in_IN those_DT
          with_IN HF_NNP :_: 47_CD -_: 48_CD %_NN in_IN those_DT with_IN HF_NNP ,_, 35_CD -_: 36_CD %_NN in_IN those_DT without_IN
          (_( 
          P_NN <_NN ._. 001_CD )_) ._. Left_NNP ventricular_NN
          hypertrophy_NN (_( LVH_NNP )_) by_IN ECG_NNP was_VBD a_DT risk_NN factor_NN in_IN 21_CD -_: 22_CD %_NN of_IN
          those_DT who_WP later_RB developed_VBN HF_NNP ,_, compared_VBN with_IN 16_CD %_NN of_IN those_DT
          in_IN each_DT group_NN who_WP did_VBD not_RB develop_VB HF_NNP (_( 
          P_NN <_NN ._. 001_CD )_) ._.
          Baseline_NNP pulse_NN pressure_NN (_( PP_NNP )_) showed_VBD some_DT variation_NN
          between_IN participants_NNS who_WP did_VBD and_CC did_VBD not_RB develop_VB HF_NNP ._. For_IN
          participants_NNS with_IN subsequent_JJ hospitalization_NN or_CC death_NN
          from_IN HF_NNP ,_, PP_NNP was_VBD 67_CD and_CC 68_CD mm_NN Hg_NNP for_IN the_DT chlorthalidone_NN
          and_CC doxazosin_NN groups_NNS ,_, respectively_RB ._. Treated_NNP ,_,
          non-hospitalized_JJ participants_NNS showed_VBD a_DT lower_JJR mean_NN
          baseline_NN PP_NNP of_IN 65_CD (_( chlorthalidone_NN group_NN )_) and_CC 64_CD mm_NN Hg_NNP
          (_( doxazosin_NN group_NN )_) ,_, and_CC an_DT even_RB lower_JJR mean_NN PP_NNP in_IN those_DT
          without_IN HF_NNP (_( 62_CD mm_NN Hg_NNP in_IN each_DT group_NN )_) ._.
        
        
          Medical_NNP Management_NNP
          Table_NNP 2_CD presents_VBZ post-event_JJ pharmacologic_JJ treatment_NN of_IN
          participants_NNS with_IN HF_NNP and_CC antihypertensive_JJ treatment_NN of_IN
          participants_NNS without_IN HF_NNP ._. Following_VBG hospitalization_NN for_IN
          HF_NNP ,_, 36_CD %_NN (_( 83_CD /_NN 232_CD )_) of_IN chlorthalidone_NN participants_NNS and_CC 45_CD %_NN
          (_( 126_CD /_NN 281_CD )_) of_IN doxazosin_NN participants_NNS remained_VBD on_IN their_PRP$
          blinded_JJ medications_NNS ._. Percentages_NNP of_IN participants_NNS on_IN
          open-label_JJ diuretics_NNS and_CC ACE-inhibitors_NNP were_VBD similar_JJ
          following_NN the_DT event_NN :_: 58_CD %_NN (_( 135_CD /_NN 232_CD )_) of_IN chlorthalidone_NN
          participants_NNS and_CC 64_CD %_NN (_( 180_CD /_NN 281_CD )_) of_IN doxazosin_NN participants_NNS
          were_VBD prescribed_VBN open-label_JJ diuretics_NNS ;_: 39_CD %_NN (_( 90_CD /_NN 232_CD )_) of_IN
          chlorthalidone_NN participants_NNS and_CC 41_CD %_NN (_( 114_CD /_NN 281_CD )_) of_IN
          doxazosin_NN participants_NNS were_VBD prescribed_VBN open-label_JJ
          ACE-inhibitors_NNP ._. Beta-blockers_NNP were_VBD prescribed_VBN for_IN 14_CD %_NN of_IN
          each_DT group_NN following_VBG the_DT event_NN ,_, which_WDT was_VBD actually_RB
          somewhat_RB less_JJR than_IN for_IN participants_NNS who_WP did_VBD not_RB develop_VB
          HF_NNP ._. Three-quarters_NNP of_IN hospitalized_VBN HF_NNP participants_NNS in_IN
          each_DT group_NN (_( 169_CD /_NN 232_CD in_IN chlorthalidone_NN group_NN ,_, 210_CD /_NN 281_CD in_IN
          doxazosin_NN group_NN )_) received_VBD at_IN least_JJS one_CD of_IN the_DT three_CD
          medications_NNS (_( diuretic_JJ ,_, ACE-inhibitor_NNP ,_, or_CC beta-blocker_NN )_)
          post-hospitalization_JJ ._.
          Among_IN participants_NNS treated_VBN but_CC not_RB hospitalized_VBN for_IN
          HF_NNP ,_, 58_CD %_NN (_( 54_CD /_NN 93_CD )_) of_IN the_DT chlorthalidone_NN group_NN and_CC 64_CD %_NN
          (_( 93_CD /_NN 145_CD )_) of_IN the_DT doxazosin_NN group_NN remained_VBD on_IN their_PRP$ blinded_JJ
          medication_NN ._. Over_IN 60_CD %_NN of_IN participants_NNS in_IN each_DT group_NN were_VBD
          prescribed_VBN open-label_JJ diuretics_NNS and_CC over_IN 30_CD %_NN received_VBD
          ACE-inhibitors_NNP ._. Open-label_NNP beta-blocker_NN use_NN post-event_JJ
          occurred_VBD in_IN 19_CD %_NN (_( 18_CD /_NN 93_CD )_) of_IN the_DT chlorthalidone_NN group_NN and_CC
          22_CD %_NN (_( 32_CD /_NN 145_CD )_) of_IN the_DT doxazosin_NN group_NN ,_, approximately_RB the_DT
          same_JJ frequency_NN as_IN in_IN participants_NNS without_IN HF_NNP ._. In_IN both_DT
          treatment_NN groups_NNS ,_, a_DT diuretic_JJ ,_, ACE-inhibitor_NNP or_CC
          beta-blocker_NN was_VBD prescribed_VBN for_IN over_IN 75_CD %_NN of_IN these_DT
          participants_NNS (_( 72_CD /_NN 93_CD in_IN chlorthalidone_NN group_NN ,_, 119_CD /_NN 145_CD in_IN
          doxazosin_NN group_NN )_) ._.
        
        
          Ejection_NNP Fraction_NNP Review_NNP
          Table_NNP 3_CD displays_NNS the_DT ejection_NN fraction_NN data_NNS ._. About_IN half_NN
          (_( 178_CD /_NN 361_CD )_) of_IN reviewed_VBN discharge_NN summaries_NNS mentioned_VBD
          ejection_NN fractions_NNS measured_VBN during_IN hospitalization_NN ,_,
          two-thirds_NNS (_( 116_CD /_NN 169_CD )_) of_IN which_WDT had_VBD quantitative_JJ
          measurements_NNS reported_VBD in_IN the_DT discharge_NN summaries_NNS (_( data_NNS
          not_RB given_VBN )_) ._. Considering_VBG only_RB the_DT earliest_JJS ejection_NN
          fraction_NN information_NN ascertained_JJ for_IN each_DT HF_NNP participant_NN ,_,
          63_CD %_NN (_( 29_CD /_NN 46_CD )_) of_IN the_DT chlorthalidone_NN and_CC 70_CD %_NN (_( 41_CD /_NN 59_CD )_) of_IN the_DT
          doxazosin_NN participants_NNS had_VBD ejection_NN fractions_NNS at_IN or_CC below_IN
          40_CD %_NN ._. Just_RB under_IN half_NN (_( 27_CD /_NN 59_CD )_) of_IN the_DT ejection_NN fractions_NNS
          reported_VBD in_IN the_DT doxazosin_NN group_NN were_VBD at_IN or_CC below_IN 30_CD %_NN ,_,
          compared_VBN with_IN one_CD third_JJ (_( 15_CD /_NN 46_CD )_) in_IN the_DT chlorthalidone_NN
          group_NN ._. Two-thirds_NNS of_IN ejection_NN fractions_NNS were_VBD obtained_VBN by_IN
          echocardiograms_NNS ,_, though_IN catheterizations_NNS accounted_VBD for_IN a_DT
          larger_JJR percentage_NN of_IN results_NNS in_IN the_DT doxazosin_NN group_NN than_IN
          in_IN the_DT chlorthalidone_NN group_NN (_( 36_CD %_NN vs_NNS ._. 24_CD %_NN )_) ._.
        
        
          Causes_NNP of_IN Death_NN and_CC 2_CD -_: Year_NNP Case-_NNP Fatality_NNP
          Causes_NNP of_IN death_NN of_IN participants_NNS with_IN previous_JJ HF_NNP
          hospitalization_NN were_VBD distributed_VBN similarly_RB in_IN the_DT two_CD
          groups_NNS ,_, with_IN slight_JJ variations_NNS ._. HF_NNP accounted_VBD for_IN 21_CD ._. 2_LS %_NN
          (_( 11_CD /_NN 52_CD )_) of_IN the_DT deaths_NNS among_IN chlorthalidone_NN participants_NNS
          and_CC 17_CD ._. 1_LS %_NN (_( 12_CD /_NN 70_CD )_) of_IN the_DT deaths_NNS among_IN doxazosin_NN
          participants_NNS ._. Over_IN half_NN of_IN the_DT deaths_NNS in_IN each_DT group_NN
          (_( 29_CD /_NN 52_CD in_IN the_DT chlorthalidone_NN group_NN ;_: 43_CD /_NN 70_CD in_IN the_DT
          doxazosin_NN group_NN )_) were_VBD due_JJ to_TO cardiovascular_JJ events_NNS ._.
          Fifteen_CD percent_NN (_( 8_CD /_NN 52_CD )_) of_IN deaths_NNS in_IN the_DT chlorthalidone_NN
          group_NN were_VBD attributed_VBN to_TO cancer_NN ,_, compared_VBN to_TO 9_CD %_NN (_( 6_CD /_NN 70_CD )_) in_IN
          the_DT doxazosin_NN group_NN (_( Table_NNP 4_LS )_) ._.
          Case-fatality_NNP for_IN participants_NNS with_IN hospitalized_VBN HF_NNP
          events_NNS showed_VBD no_DT significant_JJ differences_NNS (_( RR_NNP 0_CD ._. 96_CD ,_, 95_CD %_NN
          CI_NNP ,_, 0_CD ._. 67_CD -_: 1_CD ._. 38_CD ,_, 
          P_NN =_SYM 0_CD ._. 83_CD )_) between_IN the_DT two_CD treatment_NN
          groups_NNS (_( Figure_NN 1_LS )_) ._. Among_IN participants_NNS in_IN the_DT doxazosin_NN
          treatment_NN group_NN who_WP had_VBD been_VBN previously_RB hospitalized_VBN for_IN
          HF_NNP ,_, 22_CD ._. 1_LS %_NN (_( 70_CD /_NN 317_CD )_) subsequently_RB died_VBD ,_, compared_VBN to_TO 18_CD ._. 6_CD %_NN
          (_( 52_CD /_NN 280_CD )_) of_IN those_DT in_IN the_DT chlorthalidone_NN group_NN (_( Table_NNP 4_LS )_) ._.
          As_IN previously_RB reported_VBN ,_, all-cause_JJ mortality_NN did_VBD not_RB
          significantly_RB differ_VB in_IN the_DT two_CD treatment_NN groups_NNS (_( RR_NNP
          1_CD ._. 03_CD ,_, 95_CD %_NN CI_NNP 0_CD ._. 90_CD -_: 1_CD ._. 15_CD ,_, 
          P_NN =_SYM 0_CD ._. 56_CD )_) [_NN 2_CD ]_NN ._.
        
      
      
        Discussion_NNP
        The_DT finding_NN of_IN significantly_RB increased_VBN HF_NNP events_NNS in_IN the_DT
        doxazosin_NN group_NN compared_VBN with_IN the_DT chlorthalidone_NN group_NN
        created_VBD a_DT dilemma_NN for_IN ALLHAT_NNP ._. Since_IN the_DT trial_NN was_VBD not_RB
        designed_VBN to_TO focus_VB on_IN HF_NNP ,_, a_DT component_NN of_IN a_DT secondary_JJ
        endpoint_NN ,_, the_DT validity_NN of_IN reported_VBD HF_NNP events_NNS became_VBD an_DT
        issue_NN ._. In_IN this_DT paper_NN ,_, we_PRP have_VBP described_VBN several_JJ analyses_NNS to_TO
        address_VB this_DT concern_NN ._.
        As_IN previously_RB reported_VBN ,_, lost-to-follow-up_JJ and_CC event_NN
        documentation_NN were_VBD similar_JJ in_IN the_DT two_CD treatment_NN groups_NNS [_NN 2_CD
        ]_NN ._. Steps_VBZ employed_VBN to_TO validate_NN the_DT HF_NNP outcome_NN in_IN these_DT
        treatment_NN groups_NNS confirmed_VBD the_DT consistency_NN of_IN HF_NNP event_NN
        reporting_NN ._. Participants_NNS in_IN the_DT two_CD drug_NN groups_NNS had_VBD similar_JJ
        baseline_NN characteristics_NNS when_WRB stratified_JJ by_IN HF_NNP status_NN ._. The_DT
        differences_NNS in_IN eligibility_NN risk_NN factors_NNS between_IN those_DT
        participants_NNS with_IN HF_NNP and_CC those_DT without_IN is_VBZ not_RB surprising_JJ :_:
        larger_JJR percentages_NNS of_IN those_DT with_IN HF_NNP had_VBD a_DT history_NN of_IN MI_NNP ,_,
        stroke_NN ,_, CABG_NNP ,_, angioplasty_NN ,_, other_JJ atherosclerotic_JJ
        cardiovascular_JJ disease_NN (_( ASCVD_NNP )_) ,_, diabetes_NN ,_, low_JJ HDL_NNP levels_NNS
        and_CC ECG_NNP abnormalities_NNS ._. Nonetheless_RB ,_, these_DT eligibility_NN
        factors_NNS were_VBD not_RB substantially_RB different_JJ between_IN
        chlorthalidone_NN and_CC doxazosin_NN participants_NNS with_IN HF_NNP ._.
        Post-diagnosis_NNP pharmacologic_JJ management_NN of_IN patients_NNS is_VBZ
        one_CD measure_NN of_IN the_DT strength_NN of_IN physicians_NNS '_POS confidence_NN in_IN
        the_DT HF_NNP diagnoses_NNS ._. Open-label_NNP diuretics_NNS ,_, ACE-inhibitors_NNP and_CC
        beta-blockers_JJ ,_, all_DT recognized_VBN treatments_NNS for_IN HF_NNP ,_, were_VBD
        prescribed_VBN similarly_RB for_IN the_DT chlorthalidone_NN and_CC doxazosin_NN
        groups_NNS ,_, suggesting_VBG similar_JJ assessment_NN of_IN these_DT events_NNS in_IN
        the_DT two_CD treatment_NN groups_NNS ._.
        ALLHAT_NNP criteria_NNS for_IN HF_NNP were_VBD equivalently_RB met_VBN in_IN the_DT two_CD
        groups_NNS ._. While_IN the_DT sample_NN (_( n_NN =_SYM 50_CD )_) of_IN hospitalized_VBN or_CC fatal_JJ
        HF_NNP reports_NNS reviewed_VBN by_IN the_DT ALLHAT_NNP Endpoints_NNP Subcommittee_NNP
        was_VBD limited_JJ in_IN number_NN and_CC in_IN adequacy_NN of_IN corroborating_VBG
        documentation_NN ,_, the_DT review_NN nonetheless_RB showed_VBD adherence_NN to_TO
        study_VB criteria_NNS for_IN the_DT majority_NN (_( 85_CD %_NN )_) of_IN the_DT event_NN reports_NNS ._.
        The_DT sometimes-discrepant_JJ results_NNS between_IN reviewers_NNS
        pertained_JJ more_RBR often_RB to_TO incomplete_JJ data_NNS than_IN to_TO rejection_NN
        of_IN a_DT HF_NNP diagnosis_NN ._.
        Clinical_NNP use_NN of_IN more_JJR objective_NN measures_NNS ,_, including_VBG
        noninvasive_JJ and_CC /_NN or_CC invasive_JJ tools_NNS for_IN the_DT measurement_NN of_IN
        left_JJ ventricular_NN function_NN ,_, offers_VBZ a_DT means_NN of_IN establishing_VBG
        and_CC quantifying_VBG systolic_JJ failure_NN in_IN cases_NNS clinically_RB
        suggestive_JJ of_IN HF_NNP [_NN 7_CD 10_CD ]_NN ._. Among_IN the_DT ejection_NN fractions_NNS
        reported_VBD in_IN the_DT ALLHAT_NNP events_NNS that_WDT were_VBD reviewed_VBN ,_, the_DT
        majority_NN fell_VBD at_IN or_CC below_IN 40_CD %_NN ,_, indicating_VBG some_DT degree_NN of_IN
        systolic_JJ dysfunction_NN ._. However_RB ,_, HF_NNP is_VBZ a_DT clinical_JJ diagnosis_NN
        that_WDT does_VBZ not_RB necessarily_RB exclude_VB those_DT with_IN intact_JJ left_JJ
        ventricular_NN systolic_JJ function_NN [_NN 11_CD ]_NN ._. Hypertension_NNP is_VBZ a_DT
        major_JJ risk_NN factor_NN for_IN diastolic_JJ HF_NNP ;_: as_RB many_JJ as_IN 25_CD %_NN of_IN
        asymptomatic_JJ hypertensives_NNS with_IN left_JJ ventricular_NN
        hypertrophy_NN have_VBP diastolic_JJ dysfunction_NN ._. Additionally_RB ,_, 90_CD %_NN
        of_IN patients_NNS with_IN coronary_JJ artery_NN disease_NN may_MD have_VB some_DT
        degree_NN of_IN diastolic_JJ dysfunction_NN [_NN 12_CD ]_NN ._.
        The_DT two-fold_JJ increased_VBN relative_JJ risk_NN of_IN HF_NNP in_IN the_DT
        doxazosin_NN group_NN compared_VBN to_TO the_DT chlorthalidone_NN group_NN
        changed_VBD little_JJ when_WRB confined_VBN to_TO hospitalized_VBN and_CC fatal_JJ
        events_NNS ._. Further_RB ,_, HF_NNP patients_NNS in_IN both_DT the_DT doxazosin_NN and_CC
        chlorthalidone_NN treatment_NN groups_NNS showed_VBD a_DT rather_RB high_JJ 20_CD %_NN
        case-fatality_JJ rate_NN over_IN two_CD years_NNS ,_, as_IN expected_VBN in_IN HF_NNP
        patients_NNS [_NN 11_CD 13_CD 14_CD ]_NN ,_, further_JJ supporting_VBG the_DT validity_NN of_IN
        the_DT diagnoses_NNS in_IN the_DT two_CD groups_NNS ._. Among_IN participants_NNS
        hospitalized_VBN for_IN HF_NNP who_WP subsequently_RB died_VBD ,_, over_IN half_NN of_IN the_DT
        deaths_NNS in_IN each_DT drug_NN group_NN were_VBD attributed_VBN to_TO cardiovascular_JJ
        causes_NNS ._.
        Treatment_NNP group_NN differences_NNS in_IN mortality_NN attributed_VBD to_TO
        HF_NNP may_MD take_VB time_NN to_TO be_VB recognized_VBN ._. Patients_NNS with_IN HF_NNP are_VBP at_IN
        risk_NN for_IN other_JJ competing_VBG causes_NNS of_IN death_NN ._. Accordingly_RB ,_, it_PRP
        may_MD be_VB too_RB early_JJ to_TO determine_VB if_IN a_DT higher_JJR rate_NN of_IN HF_NNP in_IN the_DT
        doxazosin_NN group_NN translates_NNS into_IN a_DT higher_JJR overall_JJ mortality_NN
        rate_NN ._. A_DT 20_CD %_NN 2_CD -_: year_NN case-fatality_JJ rate_NN with_IN a_DT 4_CD %_NN difference_NN
        in_IN HF_NNP incidence_NN rate_NN translates_NNS into_IN a_DT 0_CD ._. 8_CD %_NN potential_JJ
        difference_NN in_IN total_JJ mortality_NN without_IN any_DT competing_VBG causes_NNS
        of_IN death_NN ._. With_IN competing_VBG causes_NNS ,_, the_DT difference_NN would_MD be_VB
        smaller_JJR and_CC difficult_JJ to_TO detect_VB even_RB in_IN a_DT trial_NN of_IN ALLHAT_NNP 's_POS
        size_NN ._.
        The_DT diagnosis_NN of_IN HF_NNP is_VBZ generally_RB made_VBN on_IN the_DT basis_NN of_IN
        signs_NNS and_CC symptoms_NNS that_WDT may_MD overlap_VB with_IN those_DT of_IN other_JJ
        cardiovascular_JJ and_CC pulmonary_JJ pathologies_NNS ._. Moreover_RB ,_, the_DT
        clinical_JJ picture_NN may_MD be_VB further_RBR complicated_VBN for_IN patients_NNS
        taking_VBG doxazosin_NN ,_, side_NN effects_NNS of_IN which_WDT (_( edema_NN ,_, dyspnea_NN ,_,
        and_CC tachycardia_NN )_) [_NN 15_CD ]_NN may_MD be_VB misinterpreted_VBN as_IN
        manifestations_NNS of_IN HF_NNP ._.
        The_DT capture_NN of_IN events_NNS in_IN a_DT "_'' large_JJ and_CC simple_JJ trial_NN "_'' such_JJ
        as_IN ALLHAT_NNP has_VBZ potential_JJ limitations_NNS ._. Built_VBN into_IN a_DT structure_NN
        composed_VBN largely_RB of_IN community-based_JJ physicians_NNS is_VBZ the_DT
        assumption_NN that_IN their_PRP$ characterization_NN of_IN clinical_JJ events_NNS
        reflects_VBZ diagnostic_JJ standards_NNS of_IN the_DT medical_JJ community_NN ,_,
        and_CC ,_, as_IN such_JJ ,_, meets_VBZ study_NN criteria_NNS ._. However_RB ,_, with_IN its_PRP$ large_JJ
        number_NN of_IN endpoints_NNS ,_, resources_NNS available_JJ to_TO ALLHAT_NNP
        precluded_VBN more_JJR than_IN modest_JJ confirmatory_NN event_NN
        documentation_NN ._. Resources_NNPS were_VBD allocated_VBN for_IN additional_JJ
        documentation_NN for_IN quality_NN control_NN validation_NN only_RB for_IN a_DT
        sample_NN of_IN the_DT primary_JJ endpoint_NN (_( MIs_NNP and_CC fatal_JJ CHD_NNP )_) and_CC for_IN
        strokes_NNS ._. While_IN all_DT reported_VBN events_NNS are_VBP reviewed_VBN at_IN the_DT CTC_NNP ,_,
        the_DT sometimes_RB incomplete_JJ supporting_VBG details_NNS in_IN
        documentation_NN may_MD not_RB allow_VB for_IN validation_NN of_IN all_DT events_NNS
        according_VBG to_TO ALLHAT_NNP criteria_NNS ._. Some_DT discharge_NN summaries_NNS and_CC
        death_NN certificates_NNS may_MD lack_NN sufficient_JJ descriptive_JJ
        information_NN needed_VBN to_TO confirm_VB the_DT clinical_JJ diagnoses_NNS ._.
        Clinic_NNP staff_NN are_VBP unable_JJ to_TO provide_VB corroborating_VBG
        documentation_NN for_IN 2_CD %_NN of_IN ALLHAT_NNP event_NN reports_NNS ._.
        Efforts_NNS to_TO authenticate_NN the_DT HF_NNP events_NNS in_IN the_DT doxazosin_NN
        and_CC chlorthalidone_NN treatment_NN groups_NNS represented_VBD a_DT desirable_JJ
        step_NN in_IN the_DT examination_NN of_IN the_DT increased_VBN rate_NN of_IN HR_NNP in_IN the_DT
        doxazosin_NN group_NN ._. All_DT methods_NNS employed_VBN provided_VBN confirmatory_NN
        evidence_NN that_IN both_DT the_DT HF_NNP diagnosis_NN and_CC the_DT difference_NN in_IN
        HF_NNP rates_NNS noted_VBD between_IN the_DT doxazosin_NN and_CC chlorthalidone_NN
        groups_NNS were_VBD valid_JJ ._. Results_NNS of_IN this_DT exploratory_JJ
        investigation_NN support_NN the_DT event_NN ascertainment_NN methods_NNS
        developed_VBN for_IN ALLHAT_NNP ,_, specifically_RB for_IN HF_NNP events_NNS ._. This_DT
        validation_NN exercise_NN further_JJ illustrates_VBZ the_DT ability_NN of_IN
        large_JJ ,_, simple_JJ trials_NNS to_TO answer_VB important_JJ public_JJ health_NN
        questions_NNS requiring_VBG large_JJ sample_NN sizes_NNS and_CC to_TO grapple_VB with_IN
        unexpected_JJ results_NNS in_IN a_DT responsible_JJ and_CC meaningful_JJ
        manner_NN ._.
      
      
        Competing_VBG Interests_NNP
        The_DT authors_NNS of_IN this_DT paper_NN disclose_VB their_PRP$ affiliations_NNS
        with_IN Aventis_NNP (_( A_DT )_) ,_, Abbott_NNP (_( AB_NNP )_) ,_, AstraZeneca_NNP (_( AZ_NNP )_) ,_, Bayer_NNP (_( B_NNP )_) ,_,
        Biovail_NNP (_( BV_NNP )_) ,_, Bristol-_NNP Myers_NNP Squibb_NNP (_( BMS_NNP )_) ,_, Forest_NNP (_( F_NN )_) ,_,
        Glaxo-_NNP SmithKline_NNP /_NN SmithKline_NNP Beecham_NNP (_( GSK_NNP /_NN SKB_NNP )_) ,_, King_NNP
        Pharmaceuticals_NNP /_NN Monarch_NNP (_( KM_NNP )_) ,_, Merck_NNP (_( M_NNP )_) ,_, Novartis_NNP (_( N_NNP )_) ,_,
        Nu-_NNP Pharm_NNP (_( NP_NNP )_) ,_, Pharmacia_NNP /_NN Upjohn_NNP (_( PHU_NNP )_) ,_, Pfizer_NNP ,_, Inc_NNP ._. (_( P_NN )_) ,_,
        Sankyo_NNP (_( SY_NNP )_) ,_, Searle_NNP (_( SE_NNP )_) ,_, Solvay_NNP (_( SV_NNP )_) ,_, Takeda_NNP (_( T_NN )_) ._. These_DT
        relate_VBP to_TO personal_JJ or_CC institutional-affiliated_JJ receipt_NN of_IN
        income_NN in_IN the_DT areas_NNS of_IN research_NN grants_NNS ,_, consultant_NN fees_NNS ,_, or_CC
        other_JJ compensation_NN :_: BRD_NNP (_( AB_NNP ,_, BMS_NNP ,_, F_NN ,_, M_NNP ,_, P_NN ,_, PHU_NNP ,_, GSK_NNP /_NN SKB_NNP )_) ,_, WCC_NNP
        (_( AZ_NNP ,_, BMS_NNP ,_, F_NN ,_, M_NNP ,_, P_NN ,_, PHU_NNP ,_, SY_NNP ,_, SE_NNP ,_, SV_NNP ,_, T_NN )_) ,_, JTW_NNP (_( A_DT ,_, B_NNP ,_, BMS_NNP ,_, F_NN ,_, KM_NNP ,_, M_NNP ,_, N_NNP ,_, P_NN )_) ,_,
        FHHL_NNP (_( AZ_NNP ,_, B_NNP ,_, BMS_NNP ,_, M_NNP ,_, NP_NNP ,_, P_NN ,_, PHU_NNP )_) ,_, LJH_NNP (_( PHU_NNP )_) ;_: the_DT other_JJ authors_NNS
        report_VBP no_DT competing_VBG interests_NNS ._.
      
      
        Additional_JJ Information_NNP
        1_LS )_) New_NNP York_NNP Heart_NNP Classification_NNP functional_JJ class_NN III_NNP :_:
        "_'' Patients_NNPS with_IN cardiac_JJ disease_NN resulting_VBG in_IN marked_JJ
        limitation_NN of_IN physical_JJ activity_NN ._. They_PRP are_VBP comfortable_JJ at_IN
        rest_NN ._. Less_RBR than_IN ordinary_JJ physical_JJ activity_NN causes_NNS fatigue_NN ,_,
        palpitation_NN ,_, dyspnea_NN ,_, or_CC anginal_NN pain_NN ._. "_'' 1994_CD Revisions_NNP to_TO
        Classification_NNP of_IN Functional_NNP Capacity_NNP and_CC Objective_NNP
        Assessment_NNP of_IN Patients_NNPS with_IN Diseases_NNP of_IN the_DT Heart_NNP :_: AHA_NNP
        Medical_NNP /_NN Scientific_NNP Statement_NNP ._.
        2_LS )_) The_DT ALLHAT_NNP Manual_NNP of_IN Operations_NNP provides_VBZ for_IN
        prescription_NN of_IN open-label_JJ medicines_NNS of_IN the_DT same_JJ class_NN as_IN
        the_DT blinded_JJ medications_NNS ,_, when_WRB a_DT compelling_JJ indication_NN
        exists_VBZ ,_, such_JJ that_IN the_DT total_JJ dose_NN of_IN the_DT added_VBN open-label_JJ
        drug_NN should_MD not_RB exceed_VB 1_CD /_NN 2_CD of_IN the_DT maximum_NN dose_NN as_IN
        recommended_VBN in_IN the_DT Sixth_NNP Report_NNP of_IN the_DT Joint_NNP National_NNP
        Committee_NNP on_IN Detection_NNP ,_, Evaluation_NNP and_CC Treatment_NNP of_IN High_NNP
        Blood_NNP Pressure_NN (_( JNC_NNP VI_NNP )_) ._. If_IN a_DT compelling_JJ reason_NN requires_VBZ a_DT
        higher_JJR dose_NN ,_, it_PRP is_VBZ permitted_VBN ._.
        3_LS )_) The_DT ALLHAT_NNP follow-up_JJ form_NN allows_VBZ for_IN reporting_NN of_IN
        open-label_JJ ACE-inhibitors_NNP and_CC diuretics_NNS ;_: among_IN
        beta-blockers_JJ ,_, only_RB atenolol_NN is_VBZ reported_VBN ._. The_DT use_NN of_IN other_JJ
        beta-blockers_JJ cannot_NN be_VB ascertained_JJ from_IN the_DT data_NNS ._.
      
    
  
